Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net Loss	$ (288,989)	$ (273,551)	$ (143,255)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	40,251	18,696	11,583
Depreciation and amortization	1,765	438	243
Amortization of debt discount and issuance costs	1,486	2,084	662
Loss on extinguishment of debt	4,851	0	0
Other items	(1,980)	1,235	(116)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,925	(5,055)	(1,918)
Deferred tax assets	0	0	208
Income tax receivable	524	476	(895)
Other assets	(10)	76	(3,065)
Accounts payable	4,315	6,441	1,249
Interest payable	(1,077)	795	282
Interest payable (related party)	15	0	0
Accrued expenses	(24,554)	23,349	18,287
Operating lease liabilities	(882)
Deferred revenue	40,000	0	0
Due to former majority shareholder	(121)	(1,839)	(1,070)
Deferred rent	0	749	295
Deferred interest payable	(2,273)	2,018	255
Other	3,582	0	0
Net cash used in operating activities	(221,172)	(224,088)	(117,255)
Cash flows from investing activities:
Purchases of marketable securities	(32,076)	0	0
Maturities of marketable securities	29,240	0	0
Purchases of property and equipment	(1,099)	(1,236)	(604)
Net cash used in investing activities	(3,935)	(1,236)	(604)
Cash flows from financing activities:
Proceeds from related party debt financing	113,700	0	0
Proceeds from third party debt financing, net of financing costs paid	0	53,974	43,751
Proceeds from stock option exercises	942	1,300	36
Settlement of former majority shareholder common shares subscribed	0	0	1
Payments on third party debt financings and redemption fees	(105,420)	0	0
Payment of annual debt administration fee to NovaQuest	(300)	(300)	0
Net cash provided by financing activities	145,926	273,899	45,645
Net change in cash, cash equivalents and restricted cash	(79,181)	48,575	(72,214)
Cash, cash equivalents and restricted cash, beginning of period	157,199	108,624	180,838
Cash, cash equivalents and restricted cash, end of period	78,018	157,199	108,624
Non-cash financing activities:
Warrants issued to Hercules	0	0	789
Supplemental disclosure of cash paid:
Income taxes	38	0	900
Interest	13,030	3,923	845
Interest (related party)	1,426	0	0
Public Equity Offering
Cash flows from financing activities:
Proceeds from issuance of common shares, net of issuance costs paid	134,458	74,391	0
Cowen and Company, LLC | Private Placement
Cash flows from financing activities:
Proceeds from issuance of common shares, net of issuance costs paid	2,546	84,052	0
Roivant Sciences, Ltd. | Private Placement
Cash flows from financing activities:
Proceeds from issuance of common shares, net of issuance costs paid	0	22,500	0
NovaQuest | Private Placement
Cash flows from financing activities:
Proceeds from issuance of common shares, net of issuance costs paid	$ 0	$ 37,982	$ 1,857